Korro Bio said it will present new OPERA platform RNA-editing chemistries at OTS2026 in Denver, underscoring continued investment in its RNA therapeutics platform. Two posters will outline expanded editing capabilities as KRRO-121 advances in Phase 1/2.
published
Korro Bio said it will present new OPERA platform RNA-editing chemistries at OTS2026 in Denver, underscoring continued investment in its RNA therapeutics platform. Two posters will outline expanded editing capabilities as KRRO-121 advances in Phase 1/2.
Latest documented BWB result
$MELI market result
Long $MELI CDS Expiring next Friday $1900/$1950 for $16 (which gives me $34 profit)
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.